HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GNC In Australia, Zola In SoCal, Recalls: Health And Wellness Industry News

This article was originally published in The Rose Sheet

Executive Summary

GNC gets Rapid about business in Australia; Zola Hydration beverage expands distribution; and spiked supplement among consumer health recalls.

You may also be interested in...



More Undeclared Allergens, Contaminated Kratom Prompt Supplement Recalls

Recalls by AdvoCare International and Independent Nutrition increase to seven the number of supplement recalls announced in 2018 after FDA, officials in state health agencies or manufacturers determined the products contained nut or milk ingredients not listed on labels. Latest recall of kratom supplements potentially contaminated with salmonella is by Club 13, which had distributed pouches and bottles of its namesake kratom Maeng Da Red nationwide in retail stores and through mail orders.

Criminal Case In PR, FTC Appeal In NY, GNC In India: Health And Wellness Industry News

GNC works with Guardian Healthcare Services to grow sales in India; FTC, NY AG appeal dismissal of Prevagen complaint; and a federal grand jury in San Juan returned a 28-count indictment charging four defendants with mail and wire fraud , trafficking in counterfeit goods, distributing a controlled substance, international money laundering and smuggling.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel